Table 1.

Clinical characteristics and plasma carbamylated lipoproteins in individuals with diabetes according to baseline eGFR

CharacteristiceGFR, ml/min per 1.73 m2
≥60≥45 to <60≥30 to <45<30
N103216112760
Age, yr53±961±863±962±8
Men/women, %51/4954/4665/3572/28
Duration of diabetes, yr12±714±816±915±8
BMI, kg/m226±426±427±427±4
Smoker, %107813
Hypertension, %59839998
Normo/micro/macroalbuminuria, %60/31/932/39/2910/30/600/13/87
Retinopathy, %35627278
Cardiovascular disease, %8223142
ACEI/ARB, %41547053
Lipid-lowering therapy, %21385868
Systolic BP, mm Hg130±19139±23144±28147±21
Diastolic BP, mm Hg77±1076±977±1175±11
Fasting glucose, mg/dl157±48148±51161±72148±53
HbA1c, %8.5±1.68.5±1.48.7±1.78.7±1.6
eGFR, ml/min per 1.73 m283±1654±438±422±6
Total cholesterol, mg/dl188±39187±46185±42180±42
Triglyceride, mg/dl115 (80–177)133 (89–177)151 (106–221)142 (106–217)
LDL cholesterol, mg/dl112±74110±38105±38101±36
HDL cholesterol, mg/dl48±1347±1444±1244±16
Carbamylated LDL, µg/ml397 (269–409)433 (249–525)502 (306–612)535 (304–650)
Carbamylated HDL, µg/ml34±1138±1248±1466±28
  • Data are expressed as mean±SD or median (interquartile range). BMI, body mass index; ACEI/ARB, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; HbA1c, hemoglobin A1c.